1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €0.43 (-90.97%). The median is €0.43 (-90.97%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
CNS increases quarterly and annual revenue and earnings per share
For the quarter ended May 31, 2026, CNS reported earnings per share of 60.39 JPY (prior year 43.96 JPY) with revenue rising 13.11% to 2.06 billion JPY. Full-year EPS was 203.31 JPY versus 147.06 JPY in the prior year. Annual revenue increased 10.98% to 7.77 billion JPY. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -2.27M | 12.54% |
| EBITDA | -2.24M | 11.27% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.96M |
Number of shares | 1.46M |
52-week high/low | €9.13 - €1.64 |
| Dividends | No |
Beta | 0.98 |
P/E ratio | -0.23 |
PEG ratio | 0.00 |
P/B ratio | 2.08 |
P/S ratio | 0.00 |
Company profile
| Name | CNS PHARMAC. INC. DL-,001 Aktie |
| CEO | Rami Levin |
| Employees | 8 |
Discover assets
Shareholders of CNS PHARMAC. INC. DL-,001 Aktie also invest in the following assets
